Postpartum Involution and Cancer: An Opportunity for Targeted Breast Cancer Prevention and Treatments?
Overview
Affiliations
Childbirth at any age confers a transient increased risk for breast cancer in the first decade postpartum and this window of adverse effect extends over two decades in women with late-age first childbirth (>35 years of age). Crossover to the protective effect of pregnancy is dependent on age at first pregnancy, with young mothers receiving the most benefit. Furthermore, breast cancer diagnosis during the 5- to 10-year postpartum window associates with high risk for subsequent metastatic disease. Notably, lactation has been shown to be protective against breast cancer incidence overall, with varying degrees of protection by race, multiparity, and lifetime duration of lactation. An effect for lactation on breast cancer outcome after diagnosis has not been described. We discuss the most recent data and mechanistic insights underlying these epidemiologic findings. Postpartum involution of the breast has been identified as a key mediator of the increased risk for metastasis in women diagnosed within 5-10 years of a completed pregnancy. During breast involution, immune avoidance, increased lymphatic network, extracellular matrix remodeling, and increased seeding to the liver and lymph node work as interconnected pathways, leading to the adverse effect of a postpartum diagnosis. We al discuss a novel mechanism underlying the protective effect of breastfeeding. Collectively, these mechanistic insights offer potential therapeutic avenues for the prevention and/or improved treatment of postpartum breast cancer.
Unraveling complexity and leveraging opportunities in uncommon breast cancer subtypes.
Pareja F, Bhargava R, Borges V, Brogi E, Canas Marques R, Cardoso F NPJ Breast Cancer. 2025; 11(1):6.
PMID: 39856067 PMC: 11760369. DOI: 10.1038/s41523-025-00719-w.
Novel Interacting Partners of MGP-40, a Chitinase-Like Protein in Buffalo Mammary Epithelial Cells.
Vijay Anand J, Jaswal S, Jena M, Kumar S, Kaushik J, Mohanty A Cell Biochem Biophys. 2024; .
PMID: 39579292 DOI: 10.1007/s12013-024-01623-z.
Leggat-Barr K, Yee D, Duralde E, Hodge C, Borges V, Baxter M Breast Cancer Res Treat. 2024; 209(1):1-14.
PMID: 39531132 PMC: 11785669. DOI: 10.1007/s10549-024-07522-4.
Gestational breast cancer: distinctive molecular and clinico-epidemiological features.
de la Haba-Rodriguez J, Minguez P, Rojo F, Martin M, Alba E, Servitja S J Mammary Gland Biol Neoplasia. 2024; 29(1):18.
PMID: 39514034 PMC: 11549163. DOI: 10.1007/s10911-024-09571-3.
Epigenetic and Immune Mechanisms Linking Breastfeeding to Lower Breast Cancer Rates.
Surdacka L, Jakubas A, Jagiello J, Danilowska K, Picheta N, Gil-Kulik P Med Sci Monit. 2024; 30:e945451.
PMID: 39497379 PMC: 11549897. DOI: 10.12659/MSM.945451.